JNJ Ticker Curator

• Yousif caution: Trimmed JNJ stake by 3% in Q4, selling 9,689 shares to hold 310,460 worth $67.7M.
• Provident optimism: New $1M position with 4,838...

• PPI Tuesday: Iran war-driven energy costs expected to lift headline PPI higher, alongside airfares and health-care prices.
• Bank earnings kickoff:...

ASCRS study highlights PureSee's edge in cataract IOLs:

• 97% of patients with residual SEQ >0.25D reported complete/most satisfaction with...

Mixed signals from institutions in JNJ's Q4 13Fs ahead of earnings:

• New stake: Jackson Square Capital LLC bought 5,275 shares (~$1.09M)
• Notable...

JNJ vs. PFE pre-Q1 earnings: Key edges for JNJ.

• Revenue surge: $88.8B in 2024 to $99.5-100.5B by 2026 post-Kenvue spin-off.
• PFE flatline: Revenue...

Earnings Outlook and Bull Case Risks

• Q1 2026 Forecasts: Analysts forecast Johnson & Johnson's Q1 2026 revenue at $24.8B (+6.8% YoY) and adjusted...

JNJ vs PFE Comparison:

• Revenue Strength: JNJ projects $99.5-100.5B in 2026 vs PFE's drop from ~$100B (2022) to $59.5B (2023).
• Dividend Edge: PFE...

Motley Fool edges JNJ as better healthcare buy while tech falters and investors eye pharma.

• Leaner ops: Post-2023 Kenvue spin-off, revenue hit...

Key pharma lobby PhRMA faces leadership change as CEO Stephen Ubl plans to resign after nearly 11 years.

• Resignation months before contract ends,...

TECNIS PureSee IOL data spotlighted at ASCRS 2026 amid 16.67% 90-day and 61.54% 1-yr TSR.

• Popular narrative: 37.4% overvalued at $174 fair value vs...

Analyst Ratings

• 🔥 Morgan Stanley: Morgan Stanley maintains Buy rating on JNJ and raises price target to $267 from $262.
• 🔥 TD Cowen: TD Cowen...

• Buy rating held with $250 PT ahead of April 14 earnings
• Recovered from largest moneymaker's exclusivity loss via Tremfya, multiple myeloma...

J&J's FDA-approved Tecnis PureSee EDOF IOL shines at 2026 ASCRS with robust trial and real-world results supporting superior performance.

• US trial...

Third-party cyber risk hits JNJ: Hackers allege February 2026 breach of InfoDesk leaked employee directories from 18 firms, including J&J, Moderna,...

Key catalysts ahead for JNJ stock:

• Q1 test (Apr 14): $2.68 EPS, $23.6B rev forecast gauges TREMFYA/CARVYKTI strength post-Stelara loss.
• Margin...

Pre-earnings tension builds as JNJ's 59.5% stock rally reflects sentiment over 6% revenue growth, with P/E at 21.88x.

• Earnings pivotal: Apr 14...

• Bold Upgrade: Analyst Terence Flynn keeps Overweight/Buy on JNJ, raising PT from $262 to $267 – up 1.91%, reflecting confidence in future...

TECNIS PureSee IOL provides high contrast sensitivity and visual acuity across distances, as confirmed by new data showcased by Johnson & Johnson at ASCRS 2026.

• J&J presented clinical data on TECNIS PureSee lens at ASCRS meeting
• 96% spectacle independence for distance vision
• 95% for intermediate vision
• 61% for near vision, with high patient satisfaction

• Rally momentum: Stock up 17% YTD and 60% over 12 months from $160s range, now ~$241.
• Analyst upgrades: UBS, HSBC, Citi, JPM, TD Cowen, MS,...